Insulinotropic hormone glucagon-like peptide-I(7-37) stimulation of proinsulin gene expression and proinsulin biosynthesis in insulinoma beta TC-1 cells.
about
Regulation of glucose homeostasis by GLP-1Mechanisms of action of glucagon-like peptide 1 in the pancreasPancreatic beta-cell overexpression of the glucagon receptor gene results in enhanced beta-cell function and massDo Incretins play a role in the remission of type 2 diabetes after gastric bypass surgery: What are the evidence?The human glucagon-like peptide-1 analogue liraglutide preserves pancreatic beta cells via regulation of cell kinetics and suppression of oxidative and endoplasmic reticulum stress in a mouse model of diabetes.The evolving place of incretin-based therapies in type 2 diabetesGlucagon-like peptide-1 synthetic analogs: new therapeutic agents for use in the treatment of diabetes mellitus.New insights concerning the glucose-dependent insulin secretagogue action of glucagon-like peptide-1 in pancreatic beta-cells.Leptin suppression of insulin secretion and gene expression in human pancreatic islets: implications for the development of adipogenic diabetes mellitus.Pioglitazone and alogliptin combination therapy in type 2 diabetes: a pathophysiologically sound treatment.A Novel Long-Acting Glucagon-Like Peptide-1 Agonist with Improved Efficacy in Insulin Secretion and β-Cell Growth.Metabolic programming: causes and consequences.Progesterone receptor membrane component 1 is a functional part of the glucagon-like peptide-1 (GLP-1) receptor complex in pancreatic β cells.Glucagon-like peptide 1 stimulates insulin gene promoter activity by protein kinase A-independent activation of the rat insulin I gene cAMP response element.Glucagon-like peptide-1 is a physiological incretin in ratA randomized, double-blind, placebo-controlled, multiple-dose, parallel-group clinical trial to assess the effects of teduglutide on gastric emptying of liquids in healthy subjects.Absence of the glucagon-like peptide-1 receptor does not affect the metabolic phenotype of mice with liver-specific G(s)α deficiency.Glucagon-like peptide 1 inhibits the sirtuin deacetylase SirT1 to stimulate pancreatic β-cell mass expansion.Incretins and amylin: neuroendocrine communication between the gut, pancreas, and brain in control of food intake and blood glucose.Optimizing the Care of Patients With Type 2 Diabetes Using Incretin-Based Therapy: Focus on GLP-1 Receptor Agonists.A novel insulinotropic mechanism of whole grain-derived γ-oryzanol via the suppression of local dopamine D2 receptor signalling in mouse isletEffect of single oral dose of proanthocyanidin on postprandial hyperglycemia in healthy rats: A comparative study with sitagliptinStructural and molecular conservation of glucagon-like Peptide-1 and its receptor confers selective ligand-receptor interaction.Incretin mimetics and dipeptidyl peptidase-IV inhibitors: potential new therapies for type 2 diabetes mellitus.Newer therapeutic options for children with diabetes mellitus: theoretical and practical considerations.Targeting glucagon receptor signalling in treating metabolic syndrome and renal injury in Type 2 diabetes: theory versus promiseGut-brain axis: regulation of glucose metabolism.Regulation of pancreatic PC1 and PC2 associated with increased glucagon-like peptide 1 in diabetic ratsNew potential adjuncts to treatment of children with type 1 diabetes mellitus.Glucagon-like peptide-1 can reverse the age-related decline in glucose tolerance in ratsMolecular mechanisms underlying physiological and receptor pleiotropic effects mediated by GLP-1R activation.Targets and probes for non-invasive imaging of β-cells.Glucagon-like peptide-1 analogues for Type 2 diabetes mellitus: current and emerging agents.Update on incretin hormones.Possible role of GLP-1 and its agonists in the treatment of type 1 diabetes mellitus.Review article: a comparison of glucagon-like peptides 1 and 2.Comparative evaluation of incretin-based antidiabetic medications and alternative therapies to be added to metformin in the case of monotherapy failure.Degradation, receptor binding, insulin secreting and antihyperglycaemic actions of palmitate-derivatised native and Ala8-substituted GLP-1 analogues.Differential Effects of Linagliptin on the Function of Human Islets Isolated from Non-diabetic and Diabetic Donors.Intra-islet glucagon-like peptide 1.
P2860
Q24563430-7AA39F43-E31F-406A-804C-3E65D7731AD4Q24683764-A0507722-9FB5-45D1-900B-962BC33FFF6CQ30490044-2B574904-EA9E-4FFC-9C06-D06406EC2252Q33789529-53658487-836E-49F6-B70E-8D3DE218762DQ33826388-299BBC8F-C435-4395-8CBA-B7DCE9A8C5AFQ33866808-AC9754B4-32FE-44F2-B9CE-59DBA14DCFA9Q34026346-D9DD2A9F-8101-4280-93E3-4B9504F53AD8Q34037472-DE72F048-9CE4-4029-8729-B99CD6F411BAQ34082576-54DEB0A8-06C0-4271-8E2D-7390AEAD9C05Q34139048-7AF28EAD-63C0-4027-9187-DDD9DD4C0EEDQ34318785-11EC46CE-90D3-4798-AAA1-505B5AB2E5C0Q34430909-28E61DEF-F49E-4FDA-B3C0-ECF46CE6E9C9Q34468359-083A49AC-850B-4B31-A1B9-1B61998636A6Q34610365-F1B1BC2D-5915-4E34-8924-DC60105C37A4Q34662409-2FE637A1-F1B8-409D-B716-1A6E647961F2Q35091974-B2FD04EA-BFB9-4D06-9D26-CDC4A2AA81EFQ35175696-A8592AB1-358F-481B-A7D7-9245626E8FEFQ35561114-9660BCD2-6AF3-49E2-B950-A854727A9779Q35690970-5E683541-2C19-4F9E-A690-24C9981F1796Q35906506-52555A15-E037-4052-A57B-0BAECC0A82B7Q36036244-C5559897-195F-4818-981A-197A6DBCAA0FQ36078084-BC59B756-1C83-4FDF-B4BB-04E20C143ABAQ36406906-528964BA-15FE-475D-A8BE-D3ED1AE14827Q36407215-2BF6E762-2B57-4D6F-A5EF-B478B3A18C45Q36455865-A54BF9E3-0BA9-44FF-9DA6-7F350FF95E54Q36514704-DCCADAAF-3C23-4B9B-A7B8-73BF3FFDCC44Q36640460-E446BD0F-2288-4249-9FA8-A556D73E0009Q37176157-30E498F9-047E-485E-A1CD-05BFCC268833Q37353820-9C7472B2-03A6-4898-BCD1-C5EC99046D79Q37368678-358EDCA0-2FF3-4760-8CC0-BDF3AFEB0156Q37635255-22AA329F-4D3C-4044-B6D2-942FA6C13F9EQ37662672-A45C0C58-945F-44C6-A1E1-B4520C1B5343Q37929159-2A49FFFF-D8C8-4E12-8047-340F95E1A67BQ38006504-6653EED0-9FB9-40A6-BE45-36D1A259BCDBQ38024321-8C511B60-7F8D-4FB9-A903-37AB6C8FCFBFQ38057350-B78E3BCC-9BD2-4AA2-B420-C1072AFDD8D5Q38213037-05B11CFB-0355-44BF-8975-E556448F84A2Q38342150-C19B4E25-7AAC-4488-8CEA-A4D2EBD81D47Q38628168-E7F4E07B-4990-4C74-977E-5474F421277DQ38856625-89ADDEB1-C1E9-44B1-9018-27D097A0EA6D
P2860
Insulinotropic hormone glucagon-like peptide-I(7-37) stimulation of proinsulin gene expression and proinsulin biosynthesis in insulinoma beta TC-1 cells.
description
1992 nî lūn-bûn
@nan
1992年の論文
@ja
1992年学术文章
@wuu
1992年学术文章
@zh
1992年学术文章
@zh-cn
1992年学术文章
@zh-hans
1992年学术文章
@zh-my
1992年学术文章
@zh-sg
1992年學術文章
@yue
1992年學術文章
@zh-hant
name
Insulinotropic hormone glucagon-like peptide-I
@nl
Insulinotropic hormone glucago ...... in insulinoma beta TC-1 cells.
@en
type
label
Insulinotropic hormone glucagon-like peptide-I
@nl
Insulinotropic hormone glucago ...... in insulinoma beta TC-1 cells.
@en
prefLabel
Insulinotropic hormone glucagon-like peptide-I
@nl
Insulinotropic hormone glucago ...... in insulinoma beta TC-1 cells.
@en
P356
P1433
P1476
Insulinotropic hormone glucago ...... in insulinoma beta TC-1 cells.
@en
P2093
H C Fehmann
J F Habener
P304
P356
10.1210/EN.130.1.159
P407
P577
1992-01-01T00:00:00Z